TLR7 and neoplasm: Taken together, the described studies provide proof of principle that a single dose of TransCon TLR7/8 Agonist mediates anti-tumor efficacy via sustained delivery of resiquimod to the tumor site while avoiding high systemic exposure and reducing the risk of AEs.